Pemigatinib
- Generic Name
- Pemigatinib
- Brand Names
- Pemazyre
- Drug Type
- Small Molecule
- Chemical Formula
- C24H27F2N5O4
- CAS Number
- 1513857-77-6
- Unique Ingredient Identifier
- Y6BX7BL23K
- Background
Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide varie...
- Indication
Pemigatinib is indicated for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously-treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
...
- Associated Conditions
- Refractory Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement, Relapsed Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement, Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas
- Associated Therapies
- -
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2022-12-15
- Target Recruit Count
- 100
- Registration Number
- NCT05651672
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-08-28
- Target Recruit Count
- 20
- Registration Number
- NCT05565794
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇩🇪Klinikum Esslingen, Esslingen, Germany
🇩🇪Klinikum Ludwigsburg, Ludwigsburg, Germany
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-18
- Target Recruit Count
- 20
- Registration Number
- NCT05287386
- Locations
- 🇨🇳
the First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT05267106
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
🇺🇸University of Illinois Hospital & Health Sciences System, Chicago, Illinois, United States
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT05253807
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States
A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2022-01-27
- Target Recruit Count
- 20
- Registration Number
- NCT05210946
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, China
A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 20
- Registration Number
- NCT05202236
- Locations
- 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT05159245
- Locations
- 🇫🇮
Turku University Hospital Cancer Centre, Turku, Varsinais-Suomi, Finland
🇫🇮Kuopio University Hospital, Kuopio, Finland
🇫🇮Oulu University Hospital OYS Cancer Center, Oulu, Finland
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-03-12
- Target Recruit Count
- 20
- Registration Number
- NCT05004974
- Locations
- 🇨🇳
The Fourth Affiliated Hospital of Zhejiang University, Yiwu, Zhejiang, China
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
- Conditions
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT04949191
- Locations
- 🇺🇸
Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States
🇺🇸Oncology Specialists of Charlotte, Charlotte, North Carolina, United States
🇮🇹Istituto Nazionale Tumori Regina Elena Irccs, Rome, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.